Initial research has focused on obesity, but Ozempic, Wegovy and Mounjaro may potentially be used for addiction, heart ...

Elon Musk validated the use of GLP-1 drugs in a post on X on Wednesday. But Robert F. Kennedy Jr. has said he's opposed to Americans using them to fight obesity.

Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and acceptably safe for the treatment of type 2 diabetes and obesity, leading to ...

Wegovy and other GLP-1 medications have become extremely popular over the past few years. Novo Nordisk (which makes both ...

A recent New York Times story described a new fad: "microdosing" GLP-1 anti-obesity drugs like semaglutide (Ozempic, Wegovy) ...

Here are 10 major orthopedic studies conducted in 2024 to know: ...

GLP-1 agonists substantially slowed kidney deterioration and failure, independent of diabetes status. The most extensive and ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Now, research from Henry Ford Health, has found that weight-loss drugs, including GLP-1, could also impact alcohol ...

Market multiples for Novo Nordisk are also attractive now, especially with a forward P/E for 2025 at 28.3x. Learn more about NVO stock here.

For a drug that has been on the market for only a year, Eli Lilly and Co.’s anti-obesity treatment Zepbound has quickly made a huge name for itself, racking up more than $3 billion in sales and ...

The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.